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Abstract
Background: Current primary prevention guidelines for cardiovascular disease (CVD) prioritize risk identification, risk
stratification using clinical and risk scores, and risk reduction with lifestyle interventions and pharmacotherapy.
Subclinical atherosclerosis is an early indicator of atherosclerotic burden and its timely recognition can slow or
prevent progression to CVD. Thus, individuals with subclinical atherosclerosis are a priority for primary prevention.
This study takes a practical approach to answering a challenge commonly faced by primary care practitioners: in
patients with no known CVD, how can individuals likely to have subclinical atherosclerosis be easily identified
using existing clinical data and/or information provided by the patient?
Methods: Using NHANES (1999–2004), 6091 men and women aged ≥40 years without any CVD comprised the
primary prevention population for this study. Subclinical atherosclerosis was determined via ankle-brachial index
(ABI) using established cutoffs (subclinical atherosclerosis defined as ABI (0.91–0.99); normal defined as ABI (1.00–
1.30)). Three common scores were calculated: the Framingham Risk Score (FRS), the Metabolic Syndrome (MetS),
and the Cardiovascular Health Index (CVHI). Logistic regression analysis assessed the association between these
scores and subclinical atherosclerosis. The sensitively and specificity of these scores in identifying subclinical
atherosclerosis was determined.
Results: In eligible participants, 3.8% had subclinical atherosclerosis. Optimum and average CVHI was associated
with decreased odds for subclinical atherosclerosis. High, but not intermediate-risk, FRS was associated with
increased odds for subclinical atherosclerosis. MetS was not associated with subclinical atherosclerosis. Of the 3
scores, CVHI was the most sensitive in identifying subclinical atherosclerosis and had the lowest number of
missed cases. The FRS was the most specific but least sensitive of the 3 scores, and had almost 10-fold more
missed cases vs. the CVHI. The MetS had “middle” sensitivity and specificity, and 10-fold more missed cases vs.
the CVHI.
Conclusions: Results from this study suggest that routine administration of the CVHI in a primary prevention
population would yield the benefits of identifying patients with existing subclinical CVD not identified through
traditional CVD risk factors or scores, and bring physical activity and nutrition to the forefront of provider-patient
discussions about lifestyle factors critical to maintaining and prolonging cardiovascular health.
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Metabolic syndrome, Cardiovascular disease prevention, Cardiovascular risk factors, Primary prevention, NHANES
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Background
Cardiovascular disease (CVD), now responsible for 1 in
every 4 deaths in the USA and the leading cause of death
globally [1], results in enormous societal burden. Primordial and primary prevention remain at the center of
strategies [2] to reduce the CVD burden and counter
projections that, despite advancements in risk-lowering
medication, up to 44% of the USA population will have
CVD by 2030 [1, 3], largely due to increased prevalence
of obesity and diabetes [2].
Current primary prevention guidelines prioritize risk
identification, principally through traditional cardiovascular disease risk factors (obesity, blood pressure, cholesterol, glucose, and smoking), risk stratification using
clinical and risk scores, and risk reduction with lifestyle
interventions and pharmacotherapy [4–9]. Numerous
clinical and risk scores, constructed using algorithms
that include varying combinations of traditional CVD
risk factors, are available to quantify CVD “risk”; [10]
three such scores are the Framingham Risk Score (FRS),
the Metabolic Syndrome (MetS), and the Cardiovascular
Health Index (CVHI).
The FRS, one of the most well-known and widely used
risk scores, was originally developed in 1998 from the
Framingham Heart Study cohort to predict 10-year risk
of coronary heart disease (CHD) based on age, gender,
smoking, cholesterol, diabetes, and blood pressure [10,
11]. It has since been extended to predict absolute risk
of a CHD-related event (stroke, myocardial infarction,
angina and peripheral vascular disease) in those without
clinical CVD [12, 13]. In contrast to the FRS, the MetS
is not a predictive score, but the simultaneous presence
of multiple traditional CVD risk factors (three of: central
obesity; low high-density lipoprotein (HDL) levels; elevated blood pressure; hyperglycemia; hypertriglyceridemia) [14], that may be additive or synergistic in
their effect on CVD development [15]. Research has
consistently demonstrated a strong association between
MetS and increased risk for cardiovascular events and
cardiovascular mortality in those with and without
known CVD [16, 17]. A comparatively new score, the
CVHI was developed in 2010 by the American Heart
Association (AHA) as a summative score to quantify
cardiovascular health (CVH), as opposed to disease or
disease risk [18]. Similar to MetS, the CVHI is an aggregate of well recognized traditional CVD risk factors
(blood pressure, total cholesterol, blood glucose, obesity)
as well as behavioral factors (smoking, diet, and physical
activity). The CVHI was intentionally designed not as a
score predictive of CVD or risk of an event, but rather a
summative score that quantifies CVH. Multiple studies,
in particular Folsom et al., have reported the strong relationship between ideal CVH and favorable outcomes,
such as lower incidence of CVD [19]. Importantly for
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primary prevention, all components of the MetS and
CVHI, but not the FRS, are modifiable through lifestyle
changes alone [20].
Atherosclerosis is a chronic, inflammatory disease of
the arteries that is the most common pathophysiologic
process underlying CVD [21]. Like all such processes,
atherosclerosis exists along a continuum from subclinical atherosclerosis to patent clinical atherosclerotic vascular disease, can start early in life, and can remain
clinically undetected throughout life until an acute event
such as myocardial infarction or stroke [21, 22]. Subclinical atherosclerosis is an early indicator of atherosclerotic burden and its timely recognition can slow or
prevent the progression to overt CVD [23]. Thus, individuals with subclinical atherosclerosis are a vital priority
for primary prevention, but simultaneously a challenge
for primary care providers to identify. In this study, we
attempt to take a practical approach to answering this
challenge commonly faced by primary care practitioners.
Specifically: in patients with no known CVD, how can
individuals who are likely to have subclinical atherosclerosis, and so in need of prompt primary prevention, be
easily identified using existing clinical data and / or
information provided by the patient? To accomplish this,
we conducted a 2-stage analysis: in the first stage, we
determined the association between subclinical atherosclerosis and three common clinical and risk scores.
Next, we determined the sensitively and specificity of
these scores in identifying those with subclinical
atherosclerosis.

Methods
We conducted a cross-sectional study using data
collected as part of the National Health and Nutrition
Examination Survey (NHANES). This study was
approved as exempt by the University of Western
Ontario Research Ethics Board and as non-human
subjects research by the West Virginia University
Institutional Review Board.
Participants

NHANES is an ongoing, nationally representative
survey conducted by the Centers for Disease Control
and Prevention (CDC) that collects data on the health
and nutrition status of persons in the USA via interviews and physical examinations. All NHANES data,
detailed collection methodology, sampling plans and
weights, and analytic guidelines are publicly available
[24]. Due to the availability of ankle-brachial index
(ABI) (discussed below), data from NHANES surveys
(1999–2000, 2001–2002 and 2003–2004) were used for
the current study.
All NHANES participants in the above 3 sampling
frames were evaluated for eligibility. To achieve a
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primary prevention population – i.e., those without diagnosed CVD – ineligible participants included those who
self-reported a previous diagnosis of CVD (based on an
affirmative response to the question, “Has a doctor or
other health professional ever told you that you had coronary heart disease, angina (also called angina pectoris),
heart attack (also called myocardial infarction), or
stroke?”. Participants were also ineligible if their measured ABI was outside the range of 0.90–1.40, as low
ABI (≤0.90) indicates peripheral arterial disease (PAD), a
systemic manifestation of clinical CVD, and high ABI
(≥1.40) indicates incompressible arteries not consistent
with atherosclerosis and so not relevant for this study.
Thus, eligible participants included individuals with:
complete data for ABI; ABI within the range of 0.90–
1.40; all variables needed to determine FRS, MetS, and
CVHI; and those without a diagnosis of CVD.
For this study of NHANES participants (1999–2004),
ABI values were measured on a total of 7571 participants aged ≥40 years. (Note: ABI is not collected in
participants < 40 years). A total of 113 subjects were
excluded due to high ABI (≥1.40). Of the remaining
7458 participants, a further 1367 were excluded with a
diagnosis of CVD or low ABI (≤0.90). Our final sample
included a total of 6091 persons, aged ≥40 years, and
without a diagnosis of CVD or PAD, which represents a
weighted total population of 87,901,942 individuals.
Outcome measure (dependent variable): subclinical
atherosclerosis

The ankle-brachial index (ABI), calculated as the ratio of
systolic blood pressure at the ankle to systolic blood
pressure at the upper arm, is a non-invasive measurement with well-established cutoff values accepted as
indicative of atherosclerosis and/or PAD [25]. While
angiography remains the gold standard for detecting atherosclerosis, ABI is an accurate and inexpensive method
to detect abnormal limb arterial blood flow and atherosclerotic disease in the peripheral arteries [26, 27]. ABI
is significantly associated with the level of subclinical
atherosclerosis found in coronary and carotid arteries,
making it a valid measure of systemic preclinical disease
[28, 29]. Borderline ABI is clinically relevant as it represents subclinical atherosclerosis in systemic vascular
beds [30] and is predictive of an increased risk of CVD
events [31].
The ABI is the only measure of subclinical atherosclerosis in NHANES. ABI values were automatically
calculated as the ratio of the systolic blood pressure
of each ankle to the blood pressure in the upper right
arm. Mean ABI of the sample was 1.15 (95% CI 1.14–
1.16). For the purposes of this study, ABI values were
defined according to the 2012 guidelines on measuring and interpreting ABI from the American College
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of Cardiology and the American Heart Association
[32]. Normal ABI was defined as a value of 1.00–1.39.
Borderline abnormal ABI, indicative of subclinical
atherosclerosis in peripheral arteries, was defined as
0.91–0.99. Mean ABI in the eligible population was
1.15 (95% CI 1.14–1.16) and was non-normally
distributed; ABI was only used as a categorical
variable in this study.
Exposure variables (independent variables): FRS, MetS,
and CVHI

For this study, three clinical and risk scores were determined for each eligible participant: the Framingham Risk
Score (FRS); the Metabolic Syndrome (MetS); and the
Cardiovascular Health Index (CVHI).
Framingham Risk Score (FRS)

The development and scoring of the FRS has been
thoroughly described elsewhere [12]. Components in
the FRS include age, total and HDL cholesterol, blood
pressure, diabetes and smoking status, all available
within NHANES. A total FRS score was calculated for
each eligible participant according to the algorithm
developed by D’Agostini et al. [33] Eligible participants with FRS scores of < 10%, 10–20%, > 20% were
classified as low-risk, intermediate-risk and high-risk
for a CVD-related event within the next 10 years,
respectively.
Metabolic Syndrome (MetS)

Classification of MetS was based on the criteria developed by the American Heart Association and the
National Heart Lung and Blood Institute [15]. This definition was chosen because it accounted for participants
being pharmacologically treated for MetS components
as well as clinical parameters, thus capturing all individuals with MetS even if clinical parameters were not
elevated at the time of testing. Three of the following
five risk factors confirmed the presence of MetS: abdominal obesity (male waist > 40 in. (101.6 cm); female waist
> 35 in. (88.9 cm)); elevated triglycerides ≥150 mg/dL
(1.69 mmol/L) or on triglyceride lowering medication;
low HDL cholesterol (male < 40 mg/dL (1.03 mmol/L);
female < 50 mg/dL (1.29 mmol/L)) or on HDL improving medication; blood pressure ≥ 130/≥85 mmHg or on
blood pressure lowering medication; fasting glucose
≥100 mg/dL (5.5 mmol/L) or on glucose lowering medication [15]. Eligible participants were classified dichotomously has having MetS (having 3 of the 5 factors
above) or not having MetS.
Cardiovascular Health Index (CVHI)

The CVHI was developed by the AHA to measure progress towards improving CVH, in contrast to focusing
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solely on measures of morbidity and mortality [18]. The
composite CVHI score is a sum of seven components
including blood pressure, cholesterol, blood glucose,
physical activity, diet, body mass index, and smoking
status [18]. The CVHI was calculated and categorized
based on criteria previously published [18] and summarized in Table 1. For this study, the composite CVHI
score was calculated on a scale of 0–14, with 2 points
awarded for achieving optimum criteria in for that component, 1 point awarded for achieving the average criteria, and 0 points for achieving only inadequate criteria.
Thus, an overall CVHI score of 10–14 points indicates
optimum CVH, 5–9 points indicates average CVH, and
0–4 points indicates inadequate CVH.
Covariates

For study participants, demographic variables abstracted
from NHANES included: age; race/ethnicity; sex;

education; and smoking. Age was categorized based on
the 2000 USA projected population age distribution categories: 40–59 years; 60–74 years; and 75 years and over.
Race was categorized as: non-Hispanic white; nonHispanic black; or other. Education was categorized as
high school education vs. no high school education.
Smoking was based on a positive response to the question: “Have you smoked at least 100 cigarettes in your
life?”

Statistical analysis

NHANES guidelines were used to merge data from years
1999–2004 and to correctly apply sampling weights,
primary sampling units, and strata. For univariate
analyses, descriptive statistics were conducted to produce weighted estimates of proportions (%) and 95%
confidence intervals (CI). For multivariable analyses, all

Table 1 Definitions for and Questions Used to Determine the Cardiovascular Health Index Scorea
Component

NHANES Question(s) / Data Used for
Component

Inadequate
(0 points)

Average
(1 point)

Optimum
(2 points)

Smoking

Based upon responses to questions: “Have
you smoked at least 100 cigarettes in your
life?”, “Do you now smoke cigarettes?”,
“How long since you last smoked cigarettes?”

Current smoker

Former smoker who quit
less than a year ago

Never smoked OR former
smoker who quit a year or
more ago

Body Mass
Index (kg/m2)

Calculated based on the height and weight
measurements obtained during the clinical
examination.

≥30 kg/m2

25.0–29.9 ≥ 30 kg/m2

< 25.0 ≥ 30 kg/m2

Physical
Activity

Based upon questions addressing intensity,
frequency and duration of physical activity.
Moderate intensity activities: those causing
“light sweating or a slight to moderate
increase in breathing or heart rate.” Vigorous
intensity activities: those causing “heavy
sweating or large increases in breathing or
heart rate”.

None

Moderate intensity (< 150
mins/wk), OR vigorous
intensity (< 75 mins/wk)

Moderate intensity (≥150 mins/
wk), OR vigorous intensity
(≥75 mins/wk) OR
Combined intensity
(≥150 min/wk)

Diet

Scored as follows: ≥4.5 cups per day of fruits
and vegetables (1 point), ≥2 servings of 3.5-oz
of fish per week (1 point), ≥3 servings of 1-oz
of fiber-rich whole grains per day (1 point),
< 1500 mg sodium per day (1 point), and
< 450 kcal of added sugar in sugar-sweetened
beverages per week (1 point).

0–1 diet points

2–3 diet points

4–5 diet points

Total
Cholesterol
(mg/dL)b

Determined according to procedures described ≥240 mg/dL
in the NHANES Laboratory/Medical Technologists [≥6.21 mmol/L]
Procedures Manual for the collecting and
storing blood samples, and for laboratory
processing of plasma lipids and glucose [49].

Blood
pressure
(mmHg)

Measured by qualified technicians after the
subjects had been sitting quietly for 5 min.
Blood pressure measurement were taken at
least 3 times on each subject and the average
of these values were used for this study.

SBP ≥140 mmHg SBP 120–139 mmHg OR
SBP < 120 mmHg and DBP < 80
OR DBP
DBP 80–89 mmHg OR
AND not on blood pressure
lowering medication
≥90 mmHg
achieved goal on blood
pressure lowering medication

Determined according to procedures described ≥126 mg/dL
Fasting
blood glucose in the NHANES Laboratory/Medical Technologists [≥7.0 mmol/L]
Procedures Manual for the collecting and storing
(mg/dL)b
blood samples, and for laboratory processing of
plasma lipids and glucose [49].
a

Components, cut-off values, and scoring criteria as defined in Lloyd-Jones et al. (2010) [18]
SI units shown in square brackets

b

200–239 mg/dL OR achieved < 200 mg/dL and not on
goal on cholesterol lowering cholesterol lowering medication
[< 5.17 mmol/L]
medication
[5.17–6.18 mmol/L)

100–125 mg/dL OR achieved < 100 mg/dL AND not on
goal on glucose lowering
glucose lowering medication
[< 5.5 mmol/L]
medication
[5.5–6.99 mmol/L]
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analyses were conducted using survey procedures to account for NHANES survey weights and sampling design.
To assess the relationship between the FRS, MetS,
CVHI and subclinical atherosclerosis, separate, independent logistic regression models were estimated. All
models were structured to produce estimates adjusted
for all covariates listed above. Interactions were tested
independently between FRS, MetS, CVHI and age, sex,
race. Tested interactions were not significant for FRS,
MetS or CVHI with age, sex or race independently (all
p > 0.05, data not shown) and so stratified analyses were
not considered further.
To assess the ability of FRS, MetS, and CVHI to
correctly identify individuals with subclinical atherosclerosis, sensitivity and specificity analyses were
performed. Sensitivity (probability of correctly detecting true-positive results) and specificity (probability of
correctly detecting true-negative results) based upon
the on the selected clinical scores (FRS, MetS, and
CVHI) were calculated using standard formulae. The
values of sensitivity and specificity are reported for
weighted estimates of the study population. Finally,
traditional CVD risk factors (blood pressure, total
cholesterol, fasting blood glucose, and body mass
index) were examined for individuals with falsenegative results – i.e., those who had subclinical atherosclerosis but were labelled as healthy or low-risk by
the FRS, MetS, or CVHI. For each score, the weighted
mean for each traditional CVD risk factor was determined for the group of individuals with false-negative
results (missed cases of subclinical atherosclerosis).
All statistical analyses were performed using Stata
Statistical Software Release 14 (College Station, TX: StataCorp LP). As all analyses were conducted using survey
procedures to account for NHANES survey weights and
sampling design, all results are reported as weighted.

Results
Characteristics in the eligible population are reported in
Table 2. Most eligible participants were aged 40–49
(40.6%), non-Hispanic white (76.9%), smokers (52.3%),
and had a high school education (81.7%). Exactly 3.4% of
the population had subclinical atherosclerosis, as defined
by borderline ABI (0.91–0.99), with the remaining 96.6%
of the study population classified as normal ABI (1.00–
1.39) and so free of subclinical atherosclerosis.
Table 3 summarizes the distribution of the outcome
and exposure variables between participants with and
without subclinical atherosclerosis. Of note, the proportion of those classified as high-risk using the FRS was
approximately doubled in the subclinical atherosclerosis
group (19.4%) as compared to those without subclinical
atherosclerosis (8.5%). There was also a higher proportion of MetS (37.2% vs 24.6%) and inadequate CVHI
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Table 2 Demographic characteristics of the eligible population
from the National Health and Nutrition Examination Survey
(1999–2004)
Weighted
Proportiona
Age category (years)
40–49

40.6 (38.5–42.8)

50–64

38.7 (36.8–39.9)

65 and older

20.7 (19.5–21.9)

Sex
Male

47.6 (46.1–49.0

Female

52.4 (50.9–53.9)

Race/Ethnicity
Non-Hispanic White

76.9 (73.4–80.0)

Non-Hispanic Black

9.3 (7.5–11.4)

Other

13.9 (10.9–17.3)

Education
Less than High School Education/no GED
(General Education Diploma)

18.3 (16.6–20.0)

High School Education/GED or more

81.7 (79.9–83.4)

Smoking
No

47.6 (45.7–49.5)

Yes (smoked at least 100 cigarettes in life)

52.3 (50.4–54.2)

a

Weighted proportion of the eligible population (n = 6091) after applying
sampling weights to the study sample (% (95% CI))

(15.8% vs 11.6%) health in those with subclinical atherosclerosis compared to those without subclinical atherosclerosis, respectively.
In Fig. 1, results from the logistic regression assessing
the association between FRS, MetS and CVHI and subclinical atherosclerosis in the eligible population are
displayed. Compared to individuals classified as lowrisk by the FRS, individuals classified as intermediaterisk were not more likely to have subclinical atherosclerosis, though individuals classified as high-risk by
the FRS were more than twice as likely to have subclinical atherosclerosis (OR 2.31; 95% CI 1.53–3.49). The
presence of MetS was only marginally associated with
increased likelihood of subclinical atherosclerosis (for
individuals with MetS compared to those without MetS
OR 1.45; 95% CI 1.00–2.11). Finally, in examining the
results for CVHI, it is noted that, compared to individuals with inadequate overall CVHI, individuals with
average overall CVHI were 29% less likely to have subclinical atherosclerosis (OR 0.71; 95% CI 0.53–0.94),
and individuals with optimum CVHI were almost 80%
less likely to have subclinical atherosclerosis (OR 0.21;
95% CI 0.08–0.54). Additionally, across all models, the
odds of having subclinical atherosclerosis were highest
for those participants aged 65 years and older, females,
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Table 3 Characteristics of the outcome and exposure variables in the eligible populationa
All

Subclinical Atherosclerosisb

No Subclinical Atherosclerosisc

–

3.4 (2.9–4.0)

96.6 (95.9–97.1)

Low risk (< 10%)

59.1 (57.8–60.4)

53.1 (0.45–61.4)

59.3 (58.0–60.6)

Intermediate risk (10%–20%)

32.1 (30.6–33.5)

27.5 (20.1–36.4)

32.2 (30.7–33.7)

High risk (> 20%)

8.9 (8.0–9.8)

19.4 (14.0–26.4)

8.5 (7.7–9.3)

No

75.0 (73.9–76.6)

62.8 (54.5–70.4)

75.4 (73.7–77.0)

Yes (3 or more components)

25.0 (23.4–26.7)

37.2 (29.6–45.5)

24.6 (23.0–26.3)

Optimum overall health (12–14 points)

12.0 (10.3–13.9)

4.4 (1.5–12.5)

13.2 (11.5–15.2)

Average overall health (8–11 points)

75.7 (73.9–77.4)

79.8 (72.7–85.4)

75.2 (73.3–77.0)

Inadequate overall health (0–7 points)

12.3 (11.0–13.7)

15.8 (11.5–21.4)

11.6 (10.3–13.0)

Ankle Brachial Index (ABI)

Statistical
Significanced

Framingham Risk Score
§

Metabolic Syndrome
§

Cardiovascular Health Indexe

§

a

Proportion estimates of the eligible population after applying sampling weights to the study sample (% (95% CI))
b
Defined as borderline ABI (0.91–0.99)
c
Defined as normal ABI (1.00–1.39)
d
Pearson’s chi squared test for comparing differences in proportions between normal ABI and borderline ABI
e
Categorization criteria and scoring for the Cardiovascular Health Index is described in Table 1
§
Indicates statistical significance at the p < 0.05 level

non-Hispanic black race, and without a high school
education (results not shown).
Results from the sensitivity and specificity analysis
are reported in Table 4. Of the scores evaluated, highrisk FRS (vs. low-risk) was both least sensitive (26.6%)
and most specific (87.4%) in identifying individuals
with subclinical atherosclerosis. Intermediate-risk FRS
(vs. low-FRS) had slightly better sensitivity (33.9%), but

also had lower specificity (64.9%). In contrast, average
CVHI (vs. optimum CVHI) was most sensitive (94.8%)
but least specific (14.9%). Inadequate CVHI (vs.
optimum CVHI) had lower sensitivity (78.0%) but
higher specificity (53.2%). MetS had better sensitivity
than both intermediate- and high-risk FRS (36.7%), but
not higher than either average or inadequate CVHI,
but had higher specificity than all but high-risk FRS at

Fig. 1 Results from logistic regression analysis assessing the association between clinical and risk scores and subclinical atherosclerosis‡.
‡
Results displayed as the Adjusted Odds Ratio and 95% Confidence Interval, with analysis conducted while applying sampling weights to the study
sample; Framingham Risk Score models adjusted for race and education; Metabolic syndrome models adjusted for sex, age, race, smoking, and
education; Cardiovascular Health Index models adjusted for sex, age, race, and education
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Table 4 Sensitivity and specificity of clinical and risk scores to identify individuals with subclinical atherosclerosisa
Framingham Risk Scored

Metabolic Syndromee

Cardiovascular Health Indexf

Intermediate Risk

High Risk

Yes

Average

Inadequate

Sensitivityb

33.9%
(33.8─33.9)

26.6%
(26.5─26.6)

36.7%
(36.6─36.7)

94.8%
(94.7─94.8)

78.0%
(77.8─78.1)

Specificityc

64.9%
(64.8─64.9)

87.4%
(87.3─87.4)

75.3%
(75.2─75.3)

14.9%
(14.8─14.9)

53.2%
(53.1─53.3)

a

Proportion estimates of the eligible population after applying sampling weights to the study sample (% (95% CI))
Sensitivity: probability of correctly detecting true positive results (individuals who do have subclinical atherosclerosis)
c
Specificity: probability of correctly detecting true negative results (individuals who do not have subclinical atherosclerosis)
d
Framingham Risk Score: Intermediate (10–20% 10-year risk) or high risk (> 20% 10-year risk) vs. low risk (referent value; < 10% 10-year risk)
e
Metabolic syndrome: Presence of metabolic syndrome (3 or more risk factors) vs. no metabolic syndrome (referent value; < 3 risk factors)
f
Cardiovascular Health Index (CVHI): Average CV health (5–9 total points) or inadequate CV health (0–4 total points) vs. optimum CV health (reference value; 10–14
total points)
b

75.3%. Table 5 details the weighted number and proportion of participants who had subclinical atherosclerosis but were not identified (missed) by the FRS, MetS
or CVHI score. The CVHI score achieved the fewest
missed cases of subclinical atherosclerosis; the FRS and
MetS had a similar number of missed cases, almost 10fold higher than the CVHI. The weighted mean of traditional cardiovascular disease risk factors for these
cases, for each score, is also reported in Table 5. These
CVD risk profiles are similar for each of the three
scores and, on average, fall within the normal range for
the risk factor – i.e., would not be identified as needing
treatment. That is, for many of these missed cases, subclinical atherosclerosis is present in the absence of being identified as at-risk by either the FRS, MetS, or
CVHI, and without abnormal traditional CVD risk
factors.

Discussion
In this study of a primary prevention population derived
from a nationally representative sample, we sought to
understand (A) the association between subclinical atherosclerosis and the 3 clinical scores FRS, MetS, and
CVHI; and (B) the ability of these different scores to
identify individuals with subclinical atherosclerosis. The
two key observations reported in this study are:
(1)Optimum and average CVHI was associated with
decreased odds for subclinical atherosclerosis. High,
but not intermediate-risk, FRS was associated with
increased odds for subclinical atherosclerosis. MetS
was not associated with subclinical atherosclerosis.
(2)Of the 3 clinical scores, CVHI was the most sensitive
in identifying cases of subclinical atherosclerosis
and had the lowest number of missed cases. The
FRS was the most specific but least sensitive of the
3 scores, and had almost 10-fold more missed cases
compared to the CVHI. The MetS had “middle” sensitivity and specificity, and 10-fold more missed cases
compared to the CVHI.

Table 5 Number, proportion, and mean values for traditional
cardiovascular disease risk factorsa of individuals misclassified as
false-negative (cases of missed subclinical atherosclerosis)
Framingham Risk Score
Missed Subclinical
Atherosclerosis
(Low Risk FRS)b

Risk Factor Profile of Missed Individuals
with Subclinical Atherosclerosis

n: 1,600,000
1.8%
(1.5─2.1)

n: 1,600,000
SBP: 137.4 mmHg (130.9–143.9)
DBP: 69.8 mmHg (66.7–72.9)
Total cholesterol: 203.8 mg/dL
(195.8–211.9) [5.27 mmol/L (5.06–5.48)]
Fasting glucose: 105.6 mg/dL
(94.5–116.8) [5.9 mmol/L (5.3–6.5)]
BMI: 28.6 kg/m2 (27.1–30.1)

Metabolic Syndrome
Missed Subclinical
Atherosclerosis
(No MetS)c

Risk Factor Profile of Missed Individuals
with Subclinical Atherosclerosis

n: 1,900,000
2.1%
(1.7─2.6)

n: 1,900,000
SBP: 139.7 mmHg (134.4–144.9)
DBP: 71.7 mmHg (69.6–73.8)
Total cholesterol: 212.8 mg/dL
(204.9–220.6) [5.51 mmol/L (5.31–5.71)]
Fasting glucose: 93.8 mg/dL (90.8–96.8)
[5.2 mmol/L (5.0–5.4)]
BMI: 27.7 kg/m2 (26.6–28.7)

Cardiovascular Health
Index
Missed Subclinical
Atherosclerosis
(Optimum CVHI)d

Risk Factor Profile of Missed Individuals
with Subclinical Atherosclerosis

n: 110,000
0.1%
(0.01─0.4)

n: 110,000
SBP: 120.9 mmHg (101.8–140.1)
DBP: 68.5 mmHg (69.9–71.7)
Total cholesterol: 175.5 mg/dL
(158.1–195.1) [4.54 mmol/L (4.09–5.03)]
Fasting glucose: 99.8 mg/dL (93.8–105.8)
[5.5 mmol/L (5.2–5.9)]
BMI: 28.6 kg/m2 (21.3–23.5)

a
Number and proportion estimates of the eligible population after applying
sampling weights to the study sample (% (95% CI)); SI units shown in
square brackets
b
Classified as “low risk” by the Framingham Risk Score (< 10% 10-year risk) but
with subclinical atherosclerosis present
c
Classified as not having the metabolic syndrome (< 3 risk factors) but with
subclinical atherosclerosis present
d
Classified as having “optimum” health by the Cardiovascular Health Index
(CVHI; 10–14 total points) but with subclinical atherosclerosis present
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To our knowledge, this study is the first to report
these observations in a nationally representative sample,
and in a primary prevention population.
Comparison to other studies

Our findings are consistent with both current knowledge
of atherogenesis as well as findings from multiple, previous studies. Prior studies of low ABI, diagnostic of PAD,
have reported strong associations between low ABI and
MetS [34] and the FRS in individuals with or without
CVD or diabetes [35]. In a recent study of participants
in the Multi-Ethnic Study of Atherosclerosis (MESA), it
was reported that adults with optimum or intermediate
CVHI were 71% and 43%, respectively, less likely to have
subclinical atherosclerosis [36]. Additionally, investigators from the Jackson Heart Study cohort have recently
described the relationship between CVHI and low ABI,
establishing a 34% increased odds of PAD in AfricanAmericans with inadequate CVHI (OR 1.34; 95% CI
1.11–1.63) [37]. Our findings extend these observations
by linking CVH, as measured by the CVHI, to subclinical atherosclerosis. The importance of the association
with subclinical atherosclerosis is that it identifies and
highlights individuals most at need for primary prevention measures so as to delay atherogenesis and prevent
the development of clinical CVD. As has been previously
discussed by others, borderline ABI represents a critical
point in the inception of atherosclerotic disease when
treatment and risk factor modification may significantly
reduce the progression of atherosclerosis and consequent occurrence of CVD [30, 38].
Our results are also consistent with a growing body of
literature describing the occurrence of CVD and cardiovascular events in those without traditional CVD risk
factor profiles; for example, a recent study by
Fernandez-Friera et al., reported that subclinical atherosclerosis existed in almost 50% of participants free of
traditional CVD risk factors [39]. Our observations extend these previous reports to a primary prevention
population: specifically, that, for a portion of the CVDfree participants in this study, subclinical atherosclerosis
was present in the absence of being identified as at-risk
by either the FRS, MetS, or CVHI, and without abnormal traditional CVD risk factors.
Implications for primary prevention: the case for the CVHI
as a routine part of primary care
.

More than 1 3 of USA adults have at least one form
.
of CVD [40] and almost 2 3 of USA adults have at
least one traditional CVD risk factor [41]. Thus, it is
a constant challenge for primary care providers to
readily identify patients most in need of prompt primary prevention: those patients without existing CVD
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and / or who may not yet meet pharmacologic treatment thresholds for traditional CVD risk factors, but
are likely to have subclinical atherosclerosis and, thus,
prompt primary prevention would prolong cardiovascular health and postpone – or prevent – the development of clinical CVD. Current USA guidelines for
the assessment and treatment of traditional CVD risk
factors include the calculation of the FRS (U.S. Preventative Services Task Force) [9] or the Pooled Cohort Equation, derived from the FRS (American Heart
Association) [5]. (Note: the Pooled Cohort Equation
was not included in this study as (a) it is only applicable in non-Hispanic whites and African-Americans
[5], which would have resulted in the exclusion of
30% of the study population sample from “other”
races; and (b) there remain ongoing debates about the
accuracy of the calibration of this score [42–46].)
However, results from this study suggest a provocative
question: in the primary prevention population, is the
CVHI a more effective tool to identify individuals in
need of prompt primary prevention?
The case for the CVHI is threefold. First, with the inclusion of the lifestyle components physical activity and
nutrition – the only score to do so – use of the CVHI
would bring these factors systematically to the fore,
which is inherently more consistent with current guidelines that specify lifestyle management as the first stage
in CVD primary prevention [4]. Second, in light of recent evidence that traditional CVD risk factors fail to
identify substantial proportions of individuals with subclinical CVD [39], it is intriguing to contemplate that
the apparent effectiveness of the CVHI in identifying
subclinical CVD may be related to the inclusion of the
physical activity and nutrition components, which may
serve as a proxy for factors associated with vascular
health not captured by traditional CVD risk factors.
Third and finally, as the CVHI is a report-card score,
measuring individuals against a standard of ideal health,
and not a predictive score such as the FRS which is designed to predict the likelihood of a particular event
within a defined time period, the CVHI largely avoids
the challenges of its accuracy and calibration changing
in different population subsets. That is, the simplicity of
the CVHI may allow it to be universally applicable
across large and diverse populations.
Thus, as risk-based scores are increasingly being incorporated into electronic health records [44, 47], results
from this study suggest that systematic inclusion of the
CVHI warrants earnest consideration. Given the overlap
in elements between risk-based CVD scores, such as the
FRS and the Pooled Cohort Equations, extension to the
CVHI would not be impracticable. While further study
is needed, results from this study suggest that routine inclusion would yield the benefits of identifying patients
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with existing subclinical CVD, and bringing physical activity and nutrition to the forefront of provider-patient
discussions about lifestyle factors critical to maintaining
and prolonging cardiovascular health.
Strengths and limitations

The primary strength of this study is the use of
NHANES, a nationally representative sample. A key
limitation is the restricted time period for ABI measurements (1999–2004) and the cross-sectional nature of
NHANES. Additionally, as NHANES did not include
any questions on symptomaticity in their subject questionnaires, temporal inferences and the prevalence of
undiagnosed CVD or PAD could not be evaluated. It is
also noted that NHANES only included ABI measures
on individuals ≥40 years of age. Future studies should
assess the comparative utility of the CVHI in younger
age groups and pre-menopausal women, where risk
prediction is challenging but, simultaneously, where primary prevention would likely yield larger gains.
Three additional caveats are warranted. First, as
described in the Methods section above, ABI in this
study was used to identify NHANES participants with
subclinical atherosclerosis; ABI is the only measurement
of subclinical atherosclerosis included in NHANES.
While ABI is strongly associated with other measures of
subclinical atherosclerosis such as carotid intima-media
thickness or the coronary artery calcification score [28],
these scores assess atherosclerotic burden in different
vascular beds so it is possible that any one of these measures does not capture all cases of subclinical atherosclerosis. Future studies could assess whether the
observations reported here are consistent across different – or a combination of – measures of atherosclerotic
burden. Second, in this study ABI was not used as a
screening tool, which is not recommended under
current USA-based guidelines [48], nor did this study
attempt to evaluate the ABI as a screening tool. ABI is
also not the singular, “gold-standard” clinical test for
atherosclerosis and was not used as such in this study.
Third, the FRS, but not the Pooled Cohort Equations,
was included in this study for the practical reasons
described above; the predictive accuracy of either score
was not assessed in this study.

Conclusions
Results from this study suggest that routine administration of the CVHI in a primary prevention population would yield the benefits of identifying patients
with existing subclinical CVD not identified through
traditional CVD risk factors or scores, and bring physical activity and nutrition to the forefront of providerpatient discussions about lifestyle factors critical to
maintaining and prolonging cardiovascular health. We
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anticipate that the findings from our study will encourage practitioners to monitor cardiovascular health even
in patients classified as low-risk by traditional disease
risk measures. It is well known that a large proportion
of CVD events occur in individuals classified as lowrisk; routine CVHI assessment may be positive step
toward the goal of reducing CVD events in the primary
prevention population.
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